Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annette M Lim

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Clinical Epigenetics|April 11, 2015
Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcomeAnnette M Lim, Ida Lm Candiloro, Nicholas Wong, et al.
Oral Oncology|February 26, 2013
Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcomeRichard J Young, Annette M Lim, Christopher Angel, et al.
International Journal of Cancer|January 18, 2014
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcomeAnnette M Lim, Hongdo Do, Richard J Young, et al.
The Lancet. Oncology|June 27, 2024
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendationsAnnette M Lim, Christophe Le Tourneau, Chris Hurt, et al.
The Lancet. Oncology|June 27, 2024
Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendationsAnnette M Lim, Lachlan McDowell, Chris Hurt, et al.
The Medical Journal of Australia|January 11, 2024
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort studyLuke S McLean, Annette M Lim, Mathias Bressel, et al.
Journal for Immunotherapy of Cancer|August 20, 2021
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysisDanny Rischin, Nikhil I Khushalani, Chrysalyne D Schmults, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingDanny Rischin, Michael R Migden, Annette M Lim, et al.
The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Journal for Immunotherapy of Cancer|March 12, 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaDanny Rischin, Brett G M Hughes, Nicole Basset-Séguin, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Clinical Epigenetics|April 11, 2015
Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcomeAnnette M Lim, Ida Lm Candiloro, Nicholas Wong, et al.
Oral Oncology|February 26, 2013
Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcomeRichard J Young, Annette M Lim, Christopher Angel, et al.
International Journal of Cancer|January 18, 2014
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcomeAnnette M Lim, Hongdo Do, Richard J Young, et al.
The Lancet. Oncology|June 27, 2024
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendationsAnnette M Lim, Christophe Le Tourneau, Chris Hurt, et al.
The Lancet. Oncology|June 27, 2024
Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendationsAnnette M Lim, Lachlan McDowell, Chris Hurt, et al.
The Medical Journal of Australia|January 11, 2024
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort studyLuke S McLean, Annette M Lim, Mathias Bressel, et al.
Journal for Immunotherapy of Cancer|August 20, 2021
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysisDanny Rischin, Nikhil I Khushalani, Chrysalyne D Schmults, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingDanny Rischin, Michael R Migden, Annette M Lim, et al.
The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Journal for Immunotherapy of Cancer|March 12, 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaDanny Rischin, Brett G M Hughes, Nicole Basset-Séguin, et al.
Pageof 5